Popular Weight-Loss drugs tested to protect kidneys from harmful fat
NCT ID NCT07309094
Summary
This study is testing if GLP-1 receptor agonist drugs (like Ozempic or Wegovy) can help control chronic kidney disease by improving unhealthy fat tissue. Researchers will enroll 250 adults with kidney disease who also have type 2 diabetes, obesity, or heart disease. The main goal is to see if these medications reduce harmful fat around the kidneys and slow the decline in kidney function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vithas Valencia Consuelo
RECRUITINGValencia, Valencia, 46007, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.